Active, Not Recruiting
ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia
NCT02029443
- Conditions
- Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +18 more
- Locations
-
- Research Site Boston, Massachusetts, United States
- Research Site New Hyde Park, New York, United States
- Research Site New York, United States
- Research Site Columbus, Ohio, United States